The react study: design of a randomized phase 3 trial to assess the efficacy and safety of clazosentan for preventing deterioration due to delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage

HIGHLIGHTS

• who: Nicolas Bruder from the Department of Anesthesia and Critical Care, Hu00f4pital de la Timone, AixMarseille Universitu00e9, rue Stu2011Pierre, Marseille, France have published the research work: The REACT study: design of a randomized phase 3 trial to assess the efficacy and safety of clazosentan for preventing deterioration due to delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage, in the Journal: (JOURNAL) of 11/03/2020
• what: The REACT study is designed to assess the safety and efficacy of in preventing clinical deterioration due to DCI in patients with aSAH. The REACT study aims at assessing the . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.